While the dollar amount is small relative to market cap, the concentration of sales among C-suite executives—especially the CEO and CFO—warrants attention. Monitor for follow-up filings or commentary around earnings or pipeline updates. Absent negative news, this is likely routine portfolio management, but the pattern should not be ignored if repeated.
Price Chart
Executive Summary
Three corporate insiders at United Therapeutics, including CEO Martine Rothblatt and CFO James Edgemond, conducted open-market sales totaling $1.08 million over a 7-day window, following a series of derivative exercises. The sales are modest in absolute value but involve key executives, raising questions about intent despite no clear signs of distress.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold 1,300 shares for $725K in open-market transactions across multiple days (April 6–9, 2026).
- CFO James Edgemond sold 680 shares for $388K, including a $322K sale on April 9.
- EVP & General Counsel Paul Mahon sold 514 shares for $288K on April 2.
- Total open-market sales: $1.08M, representing 0.0043% of the company's $25.2B market cap.
- Multiple non-cash derivative exercises occurred concurrently, accounting for the majority of transaction volume but $0 economic outflow.
Financial Impact
$1.08 million in net open-market selling by insiders
Risk Factors
- Perception of insider skepticism if sales continue or accelerate in next quarter
- Potential misinterpretation of derivative exercises as selling pressure when they are non-cash events
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1775853196702 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $500.35 $497.31 | ▼ −0.61% | ▼ −2.72% | $571.38 (+14.20%) |
Sep 11, 2026 21d ago | Insider Cluster | $497.11 $494.63 | ▼ −0.50% | ▼ −0.28% | $571.38 (+14.94%) |
Sep 10, 2026 22d ago | Insider Cluster | $503.86 $497.27 | ▼ −1.31% | ▼ −0.81% | $571.38 (+13.40%) |
Sep 9, 2026 23d ago | Insider Cluster | $506.82 $498.48 | ▼ −1.65% | ▼ −0.99% | $571.38 (+12.74%) |
Sep 4, 2026 28d ago | Insider Cluster | $487.61 $502.70 | ▲ +3.09% | ▲ +4.30% | $571.38 (+17.18%) |
Sep 3, 2026 29d ago | Insider Cluster | $488.16 $497.11 | ▲ +1.83% | ▲ +2.98% | $571.38 (+17.05%) |
Aug 28, 2026 5w ago | Insider Cluster | $515.46 $487.61 | ▼ −5.40% | ▼ −5.51% | $571.38 (+10.85%) |
Aug 27, 2026 5w ago | Insider Cluster | $527.91 $492.02 | ▼ −6.80% | ▼ −6.03% | $571.38 (+8.23%) |
Aug 26, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
Aug 25, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access